Table 2. Characteristics of peptide fragments used for human IgE-binding dot-blot assays.
| Peptide No. | IgE reactivity (%) | N-terminal sequence | Mass (Da) [M+H]+ | Position in Pen c 13 |
| S1 | 10 | ANVVQ | 2013.0 | Ala1-Lys19 |
| S2 | – | TGTTS | 1008.4 | Thr21-Asp29 |
| S3 | – | TYDST | 1336.5 | Thr27-Tyr39 |
| S4 | 70 | STAGE | 2154.0 | Ser30-Asp51 |
| S5 | 10 | GVDTG | 1362.6 | Gly40-Phe52 |
| S6 | – | FGGRA | 1406.4 | Phe52-Asp64 |
| S7 | 10 | WGTNV | 2814.0 | Trp58-Lys85 |
| S8 | 10 | YGVAK | 537.4 | Tyr86-Lys90 |
| S9 | – | KATLV | 829.0 | Lys91-Lys98 |
| S10 | 60 | VAVKV | 2220 | Val95-Trp117 |
| S11 | 50 | VLGAD | 2121 | Val99-Lys120 |
| S12 | 20 | AKSRG | 1970 | Ala122-Glu140 |
| S13 | – | YVMNM | 1462.0 | Tyr131-Lys143 |
| S14 | – | SKAVN | 1691.0 | Ser142-Phe158 |
| S15 | – | AVNDA | 1071.0 | Ala144-Lys154 |
| S16 | 90 | AAANV | 1818.0 | Ala148-Glu166 |
| S17 | – | NASNS | 1105.1 | Asn169-Glu180 |
| S18 | 50 | VCTIA | 2442.0 | Val181-Asp204 |
| S19 | 60 | TNFGS | 2771.0 | Thr197-Leu224 |
| S20 | – | SGTSM | 1489.0 | Ser225-Tyr240 |
| S21 | – | AAPHV | 1222.2 | Ala230-Met242 |
| S22 | 100 | ALEGV | 3438.0 | Ala243-Lys274 |
| S23 | – | IVQLA | 1174.0 | Ile256-Arg266 |
| S24 | – | LLYNG | 905.5 | Leu275-Val282 |
The purity of the peptides was assessed by N-terminal sequencing.
N-terminal residues were determined by Edman degradation.
Mass was determined using a QSTAR XL mass spectrometer.